---
id: market_003
type: market
topic: Oncology competitive landscape
disease: Various cancers
molecule: Multiple
---

Market Intelligence: Oncology Market Consolidation and ADC Revolution

Date: December 2024

Market Size: Global oncology market reached $220 billion in 2024, representing 20% of total pharma market.

Hot Segment - Antibody-Drug Conjugates (ADCs):
- $12 billion market in 2024, projected $35 billion by 2030
- Enhertu (Daiichi Sankyo/AstraZeneca): Blockbuster trajectory
- Major M&A: Pfizer acquired Seagen for $43 billion
- 100+ ADCs in clinical development

Checkpoint Inhibitor Maturation:
- PD-1/PD-L1 market growth slowing (6% CAGR vs 25% historically)
- Keytruda patent cliff 2028 creating opportunity window
- Biosimilar competition expected post-2028

Emerging Modalities:
- Bispecific antibodies: Rapid approvals in hematologic malignancies
- Radiopharmaceuticals: Novartis investing heavily
- TIL therapy: Lifileucel approved for melanoma

Investment Signal: POSITIVE on ADC segment. Defensive on checkpoint inhibitors. Watch Merck's Keytruda lifecycle management strategy.

